SARAH LONG: Open Payments
NPI 1376825380 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,955 in 69 payments from 17 companies in 2025. Trend: 2023 $1,654 · 2024 $1,561 · 2025 $1,955
Food & beverage: $1,955
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $499 |
| Janssen Biotech, Inc. | 12 | $498 |
| Madrigal Pharmaceuticals | 4 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $129 |
| Gilead Sciences, Inc. | 4 | $99 |
| GENZYME CORPORATION | 3 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $69 |
| QOL Medical, LLC | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Organon LLC | 2 | $38 |
Products named: TREMFYA, REZDIFFRA, SKYRIZI, RINVOQ, DUPIXENT, CREON, XIFAXAN, Sucraid.
Industry payments across IN — which companies pay providers there.
